Eon-Duval
Alex Eon-Duval, Vevey CH
Patent application number | Description | Published |
---|---|---|
20100190961 | PROCESS FOR THE PURIFICATION OF FC-CONTAINING PROTEINS - The invention relates to a process for reducing the concentration of free Fc-moieties in a fluid comprising an Fc-containing protein comprising a cation exchange chromatography step. | 07-29-2010 |
20100249381 | Method for Purifying FC-Fusion Proteins - The invention relates to a method for the purification of Fc-fusion via blue dye affinity chromatography, in particular for the reduction of the amount of free Fc-moieties in an Fc-fusion proteins preparation. | 09-30-2010 |
20100267932 | PROCESS FOR THE PURIFICATION OF FC-FUSION PROTEINS - The invention relates to a process for the purification of an Fc-fusion protein having a pI between 6.9 and 9.5 comprising protein A or G affinity chromatography, cation exchange chromatography, anion exchange chromatography and hydroxyapatite chromatography. | 10-21-2010 |
Alex Eon-Duval, Vevy CH
Patent application number | Description | Published |
---|---|---|
20100022757 | Process for the Purification of FC-Containing Proteins - The invention relates to a process for the purification of an Fc-containing protein based on cation exchange chromatography. | 01-28-2010 |
Alex Eon-Duval, Villeneuve CH
Patent application number | Description | Published |
---|---|---|
20120202974 | PROCESS FOR THE PURIFICATION OF FC-CONTAINING PROTEINS - The invention relates to a process for the purification of an Fc-containing protein based on cation exchange chromatography. | 08-09-2012 |
Alexandre Eon-Duval, Fenil-Sur-Corsier CH
Patent application number | Description | Published |
---|---|---|
20110245470 | IMMUNOGLOBULINS - The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods. | 10-06-2011 |